Courtesy of Benzinga.
In a report published Wednesday, analysts at Morgan Stanley maintained their Overweight rating on Valeant Pharmaceuticals Intl., Inc. (NYSE: VRX), as well as the price target of $223. The company announced 1Q results slightly above the consensus, while also sharing its CFO succession plan.
Valeant reported 1Q revenues and EPS above the consensus expectations while raising the midpoint of its 2015 EPS guidance range and reiterating its 2016 projections. The company has also guided to organic growth in same store sales of more than 10 percent from 2Q to 4Q of 2015.
Valeant also announced the current CFO, Howard B Schiller intends to step down as soon as a successor is appointed. Schiller will continue to serve as the CFO while the search for his successor is conducted. He will, however, continue to serve on the company’s board and stand for re-election as a director at the annual shareholder meeting to be held in May.
Latest Ratings for VRX
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 2015 | Barclays | Maintains | Overweight | |
| Apr 2015 | Deutsche Bank | Maintains | Hold | |
| Apr 2015 | JP Morgan | Reinstates | Overweight |
View More Analyst Ratings for VRX
View the Latest Analyst Ratings
Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings
